Inclusion Criteria:

        Part 1 - Eligibility Criteria for Neoadjuvant Chemotherapy

          -  Patients must have histologically confirmed invasive cervical cancer with
             adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring ≥2cm
             to <4cm by radiological imaging (MRI).

          -  Patients must be premenopausal and wish to preserve fertility.

          -  At time of registration, patient may not have had any prior therapy to treat their
             cancer lesion.

          -  Eastern Cooperative Group (ECOG) performance status ≤ 2.

          -  Within 7 days of the proposed start of treatment, patients must have normal organ and
             marrow function.

          -  No evidence of active uncontrolled infection (patients on antibiotics are eligible).

          -  Patient must have disease that is measurable per the Response Evaluation Criteria in
             Solid Tumors (RECIST) 1.1.

          -  Ability to understand and willing to sign a written informed consent document.

          -  Patients must agree to use effective contraceptive methods prior to study entry,
             during study participation, and for at least one year after the fertility-sparing
             surgery (FSS) procedure. A serum pregnancy test within 72 hours prior to study
             registration is required.

        Part 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS)

          -  Completed 3 cycles of neo-adjuvant chemotherapy and achieved a complete response (CR)
             or partial response (PR) with reduction of the lesion to <2 cm on physical examination
             and MRI.

        Exclusion Criteria:

        Part 1 - Exclusion Criteria for Neoadjuvant Chemotherapy

          -  Patients who have had chemotherapy or radiotherapy or surgery for their cancer.

          -  Patients who are receiving any other investigational agents.

          -  Patients with other cancers requiring ongoing treatment.

          -  Patients with known / evidence of brain metastases are excluded from participation in
             this clinical trial.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to paclitaxel, carboplatin, or cisplatin or other agents used in study.

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients who are pregnant or breastfeeding

          -  Any other condition that would, in the Investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures, e.g., infection/inflammation, intestinal obstruction,
             unable to swallow medication, social/ psychological issues.

        Part 2 - Exclusion Criteria for Fertility Sparing Surgery

          -  Patient unable to complete 3 cycles of neoadjuvant chemotherapy

          -  Suboptimal response to neoadjuvant chemotherapy according to investigator

          -  Residual lesion > 2cm or disease progression while on chemotherapy